885276-23-3

Basic information

• Product Name: 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE
• Synonyms: 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE;IMidazo[1,2-a]pyridine, 3-iodo-6-Methyl-;3-iodo-6-methylH-imidazo[1,2-a]pyridine
• CAS NO: 885276-23-3
• Molecular Formula: C8H7IN2
• Molecular Weight: 258.06
• Mol File: 885276-23-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.89±0.1 g/cm3(Predicted)
• PKA: 4.46±0.50(Predicted)
• CAS DataBase Reference: 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE(885276-23-3)
• EPA Substance Registry System: 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE(885276-23-3)

Safety Data

• Hazardous Substances Data: 885276-23-3(Hazardous Substances Data)

Usage

General Description

3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE is a chemical compound with the molecular formula C8H7IN2. It belongs to the class of heterocyclic compounds and is derived from imidazo[1,2-a]pyridine, which is an aromatic organic compound. This chemical is characterized by the presence of an iodo substituent at the 3-position and a methyl group at the 6-position. It has potential applications in the field of medicinal chemistry and drug development due to its unique structure and potential biological activities. 3-IODO-6-METHYL-IMIDAZO[1,2-A]PYRIDINE may be used as a building block in the synthesis of various pharmaceutical compounds and may also have biological effects that make it a target for research in drug discovery and development.

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 874-38-4 6-methylimidazo[1,2-a]pyridine 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.